Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

J Clin Oncol · 2025 · PMC12225732 · PMID 40311141

Europe PMC DOI

hedged sentence

0.0797

closest p · 1.6× alpha

0.0797

boldest claim

The sentences

did not reach statistical significanceP = .0797so close (0.05 < p ≤ 0.1)

In a prespecified sensitivity analysis censoring for COVID-19 deaths, the difference in OS did not reach statistical significance (HR, 0.75 [95% CI, 0.53 to 1.04]; P = .0797; Fig 2 D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.